Dublin, March 31, 2026 (GLOBE NEWSWIRE) — The “Wilms Tumor Protein Market Report 2026” has been added to ResearchAndMarkets.com’s offering. The report provides a comprehensive analysis, covering market statistics, regional shares, competitor data, market segments, trends, and opportunities.
The Wilms tumor protein market has shown substantial growth and is projected to continue expanding over the coming years. The market size is anticipated to increase from $3.41 billion in 2025 to $3.61 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.8%. This uptrend is driven by advancements in molecular biology research, rising use of immunohistochemistry, demand for cancer biomarkers, advancements in recombinant protein production, and heightened investments in academic research.
Looking forward, the market is projected to reach $4.71 billion in 2030, at a CAGR of 6.9%. This forecasted growth is supported by the increasing adoption of precision medicine, demand for targeted cancer diagnostics, expansion of gene-based therapeutic research, and integration of biomarkers in treatment planning. Key trends anticipated include the growing use of WT1 as a cancer biomarker, demand for molecular diagnostic tools, and enhanced focus on gene expression analysis.
The escalating incidence of kidney cancers significantly contributes to the market’s expansion. Kidney cancer presents abnormal cell growth in the kidney tissue, with WT1 expression playing a critical role in its diagnosis. The American Cancer Society reported approximately 81,800 new kidney cancer cases in 2023 alone. Additionally, projections by Cancer Research UK estimate around 21,900 new cases annually by 2038-2040, underscoring the increasing need for Wilms tumor protein in diagnostics.
Companies are prioritizing the development of advanced detection techniques. Charles River Laboratories launched an ELISA Kit in February 2023 for detecting and quantifying residual host cell proteins (HCPs), using avian IgY antibodies sourced from SPF chicken eggs. This innovation illustrates a commitment to precision in protein detection.
Major market players include Thermo Fisher Scientific, Abcam plc, BioLegend Inc., Cell Signaling Technology, and more. In December 2023, Danaher Corporation acquired Abcam plc for $5.7 billion, aiming to leverage Abcam’s advanced antibody portfolio for strengthening its life sciences offerings.
As of 2025, North America held the largest share of the Wilms tumor protein market. Regions covered include Asia-Pacific, Western and Eastern Europe, South America, and others, with significant presence in countries such as the USA, UK, Canada, China, and Germany.
Reasons to Purchase:
- Obtain a comprehensive global perspective with coverage across 16 geographies.
- Evaluate macro factors such as geopolitical tensions, trade policies, tariffs, inflation, and interest rates.
- Develop strategies tailored to regional and national data and analysis.
- Pinpoint growth areas ripe for investment.
- Outperform competitors with foresight on market drivers and trends.
- Gain insights into the end-user landscape for customer understanding.
- Benchmark against key competitors regarding market share, innovation, and brand strength.
- Assess the total addressable market (TAM) and market attractiveness scoring to gauge potential.
- Utilize high-quality data and analysis to supplement internal and external presentations.
- Receive the latest data updates with a convenient Excel data sheet for analysis.
Markets Covered:
- By Product Type: Antibodies; Assay Kits; Recombinant Proteins; Other Types
- By Detection Method: IHC; ELISA; Western Blotting; PCR; Other Methods
- By Application: Cancer Diagnosis; Cancer Treatment; R&D; Other Applications
- By End User: Hospitals; Diagnostic Laboratories; Research Institutes; Other End Users
Geographies Covered: Australia, Brazil, China, France, Germany, India, and more.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $3.61 Billion |
| Forecasted Market Value (USD) by 2030 | $4.71 Billion |
| Compound Annual Growth Rate | 6.9% |
| Regions Covered | Global |
The companies featured in this Wilms Tumor Protein market report include:
- Thermo Fisher Scientific Inc.
- Abcam plc
- BioLegend Inc.
- Cell Signaling Technology Inc.
- Genetex Inc.
- Proteintech Group Inc.
- Novus Biologicals LLC
- OriGene Technologies Inc.
- Boster Biological Technology
- ZS Genetics Inc.
- Sino Biological Inc.
- LI-COR Inc.
- QIAGEN NV
- PerkinElmer Inc.
- Oxford Nanopore Technologies plc
- Pacific Biosciences of California Inc.
- Santa Cruz Biotechnology Inc.
- SELLAS Life Sciences Inc.
- Immatics NV
- TapImmune Inc.
- Generex Biotechnology Corp
- BrightPath Biotherapeutics Inc.
For more information about this report visit https://www.researchandmarkets.com/r/5omnmf
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Wilms Tumor Protein Market
